Literature DB >> 20674017

Should minimal residual disease monitoring be the standard of care for all patients with acute promyelocytic leukemia?

David Grimwade, Martin S Tallman.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20674017     DOI: 10.1016/j.leukres.2010.06.018

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  4 in total

1.  Quantification of PML/RARa transcript after induction predicts outcome in children with acute promyelocytic leukemia.

Authors:  Li Zhang; Zeng Cao; Yao Zou; Min Ruan; Qinghua Li; Jianxiang Wang; Xiaofan Zhu
Journal:  Int J Hematol       Date:  2012-03-10       Impact factor: 2.490

Review 2.  Curing all patients with acute promyelocytic leukemia: are we there yet?

Authors:  Muhamed Baljevic; Jae H Park; Eytan Stein; Dan Douer; Jessica K Altman; Martin S Tallman
Journal:  Hematol Oncol Clin North Am       Date:  2011-12       Impact factor: 3.722

3.  Autologous is superior to allogeneic hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission.

Authors:  Jennifer L Holter Chakrabarty; Morel Rubinger; Jennifer Le-Rademacher; Hai-Lin Wang; Andrew Grigg; George B Selby; Jeffrey Szer; Jacob M Rowe; Daniel J Weisdorf; Martin S Tallman
Journal:  Biol Blood Marrow Transplant       Date:  2014-03-30       Impact factor: 5.742

4.  Development of real-time quantitative polymerase chain reaction assays to track treatment response in retinoid resistant acute promyelocytic leukemia.

Authors:  Jelena V Jovanovic; Kristian Rennie; Dominic Culligan; Andrew Peniket; Anne Lennard; Justin Harrison; Paresh Vyas; David Grimwade
Journal:  Front Oncol       Date:  2011-10-25       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.